Regulus slips after latest round of HCV data

Regulus Therapeutics Inc. (NASDAQ:RGLS) presented updated interim HCV data on Friday from a 79-patient Phase II trial of a four-week regimen of RG-101 plus a direct-acting antiviral (DAA). The company shed $0.90 (11%) to $7.23 on Friday.

Regulus said four weeks of RG-101 plus one of three DAAs led to viral responses in all but one of 41 treatment-naive patients infected with HCV genotype 1 or 4 evaluable 12 weeks after treatment. A viral response was defined as HCV viral load below the level of quantification. ...